Treatment options

• Adrenaline
• Follow-up treatment
• Guidelines
  • NICE 2011
  • Resuscitation Council (UK)
  • Royal College Paediatrics and Child Health 2011
  • Guidelines in Emergency Medicine Network (GMENet) 2009

Further information:

Prescribing Information

Patient Information Leaflet

Resuscitation Council (UK)^{25, 45}

Intended for HCPs who are expected to recognise and treat an anaphylactic reaction as part of their clinical role:

• Early treatment with intramuscular adrenaline is the treatment of choice for patients having an anaphylactic reaction
• Dose of adrenaline: − ≤6 years: 150 μg; 6 to 12 years: 300 μg; adults and adolescents (>12 years): 500 μg
• Patients should be observed in a clinical area for at least 6 hours, reviewed and potentially observed for longer periods before discharge

• An auto-injector is an appropriate treatment for patients at increased risk of an idiopathic anaphylactic reaction, or for anyone at continued high risk of reaction e.g. to triggers such as venom stings and food-induced reactions (unless easy to avoid).
• An auto-injector is not usually necessary for patients who have suffered drug induced anaphylaxis, unless it is difficult to avoid the drug.
• Guidance for auto-injector use must allow a greater degree of safety in terms of dose and recommended dosing interval
• Individuals provided with an auto-injector on discharge from hospital must be given instructions and training and have appropriate follow-up including contact with the patient’s general practitioner.